The Cyclin Dependent Kinase 12 pipeline drugs market research report outlays comprehensive information on the Cyclin Dependent Kinase 12 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cyclin Dependent Kinase 12 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Ovarian Cancer, and Breast Cancer. It also reviews key players involved in Cyclin Dependent Kinase 12 targeted therapeutics development with respective active and dormant or discontinued products.
The Cyclin Dependent Kinase 12 pipeline targets constitutes close to 11 molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in IND/ CTA Filed, Preclinical, and Discovery stages are 1, 8, and 1 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Cyclin Dependent Kinase 12 overview
Cyclin-dependent kinase 12 (CDK12) is a protein kinase that plays a critical role in the regulation of gene transcription and DNA damage repair. CDK12 is part of the cyclin-dependent kinase (CDK) family, which includes a group of enzymes involved in regulating the cell cycle and transcriptional processes. CDK12 is primarily known for its role in transcription. It associates with cyclin K (a regulatory subunit) and phosphorylates the C-terminal domain of RNA polymerase II (Pol II), a critical enzyme involved in transcribing messenger RNA (mRNA). CDK12 also has a role in DNA damage repair. It contributes to the repair of DNA double-strand breaks and the maintenance of genome stability.
For a complete picture of Cyclin Dependent Kinase 12’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
